S-3-1, a synthetic intermediate of SAA, can suppress the overexpression of the c-myc oncogene, inhibit the function of the Ras oncoprotein, increase the expression of the P53 tumour suppressor, and interrupt P46-associated and mitogen-activated pathways distinct from farnesylation of Ras [26]. Here, MYC is linked to neoplasm.